Tuesday, 16 October 2018

VistaGen nabs Japanese patent

12 June 2018 | News

The Japanese patent is like U.S. Patent awarded in December 2017.

Singapore – VistaGen Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative product candidates for patients with diseases and disorders involving the central nervous system. Recently, it announced that the Japanese Patent Office has issued a Notice of Allowance for a patent covering certain methods for producing blood cells, platelets and bone marrow stem cells.

It says the Japanese patent is like U.S. Patent awarded in December 2017.

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account

Survey Box

Do Asian patients need medicines designed for them?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls